Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

Vivelle-Dot

&times

Overview

What is Vivelle-Dot?

Vivelle-Dot (estradiol transdermal system) contains estradiol in a multipolymeric adhesive. The system is designed to release estradiol continuously upon application to intact skin.

Five dosage strengths of Vivelle-Dot are available to provide nominal delivery rates of 0.025, 0.0375, 0.05, 0.075, or 0.1 mg of estradiol per day via the skin. Each corresponding system has an active surface area of 2.5, 3.75, 5.0, 7.5, or 10.0 cm and contains 0.39, 0.585, 0.78, 1.17, or 1.56 mg of estradiol USP, respectively. The composition of the systems per unit area is identical.

Estradiol USP is a white, crystalline powder, chemically described as estra-1,3,5 (10)- triene-3,17β-diol.

The structural formula is:

The molecular formula of estradiol is CH0. The molecular weight is 272.39.

Vivelle-Dot is comprised of 3 layers. Proceeding from the visible surface toward the surface attached to the skin, these layers are (1) a translucent polyolefin film (2) an adhesive formulation containing estradiol, acrylic adhesive, silicone adhesive, oleyl alcohol, NF, povidone, USP and dipropylene glycol, and (3) a polyester release liner which is attached to the adhesive surface and must be removed before the system can be used.

The active component of the system is estradiol. The remaining components of the system are pharmacologically inactive.



What does Vivelle-Dot look like?



What are the available doses of Vivelle-Dot?

Transdermal system: 0.025 mg/day, 0.0375 mg/day, 0.05 mg/day, 0.075 mg/day, and 0.1 mg/day ()

What should I talk to my health care provider before I take Vivelle-Dot?

How should I use Vivelle-Dot?

Vivelle-Dot is indicated for:

Generally, when estrogen is prescribed for a postmenopausal woman with a uterus, a progestin should be considered to reduce the risk of endometrial cancer. A woman without a uterus does not need a progestin. In some cases, however, hysterectomized women with a history of endometriosis may need a progestin .

Use of estrogen-alone or in combination with a progestin, should be with the lowest effective dose and the shortest duration consistent with treatment goals and risks for the individual woman. Postmenopausal women should be reevaluated periodically as clinically appropriate to determine whether treatment is still necessary.

The adhesive side of Vivelle-Dot should be placed on a clean, dry area of the trunk of the body (including the abdomen or buttocks). .

Vivelle-Dot should be replaced twice weekly. The sites of application must be rotated, with an interval of at least 1 week allowed between applications to a particular site. The area selected should not be oily, damaged, or irritated. The waistline should be avoided, since tight clothing may rub the system off. The system should be applied immediately after opening the pouch and removing the protective liner. The system should be pressed firmly in place with the palm of the hand for about 10 seconds, making sure there is good contact, especially around the edges. In the event that a system should fall off, the same system may be reapplied. If the same system cannot be reapplied, a new system should be applied to another location. In either case, the original treatment schedule should be continued. If a woman has forgotten to apply a patch, she should apply a new patch as soon as possible. The new patch should be applied on the original treatment schedule. The interruption of treatment in women taking Vivelle-Dot might increase the likelihood of breakthrough bleeding, spotting and recurrence of symptoms.


What interacts with Vivelle-Dot?

Sorry No Records found


What are the warnings of Vivelle-Dot?

Sorry No Records found


What are the precautions of Vivelle-Dot?

Sorry No Records found


What are the side effects of Vivelle-Dot?

Sorry No records found


What should I look out for while using Vivelle-Dot?

Vivelle-Dot is contraindicated in women with any of the following conditions:

Estrogen-Alone Therapy

Endometrial Cancer

There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adding a progestin to estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding

[see Warnings and Precautions (5.2)].

Cardiovascular Disorders and Probable Dementia

Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or dementia

[see Warnings and Precautions (5.1, 5.3), and Clinical Studies (14.3, 14.4)].

The Women's Health Initiative (WHI) estrogen-alone substudy reported increased risks of stroke and deep vein thrombosis (DVT) in postmenopausal women (50 to 79 years of age) during 7.1 years of treatment with daily oral conjugated estrogens (CE) [0.625 mg]-alone, relative to placebo

[see Warnings and Precautions (5.1), and Clinical Studies (14.3)].

The WHI Memory Study (WHIMS) estrogen-alone ancillary study of the WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 5.2 years of treatment with daily CE (0.625 mg)-alone, relative to placebo. It is unknown whether this finding applies to younger postmenopausal women

[see Warnings and Precautions (5.3), Use in Specific Populations (8.5), and Clinical Studies (14.4)].

In the absence of comparable data, these risks should be assumed to be similar for other doses of CE and other dosage forms of estrogens.

Estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.

Estrogen Plus Progestin Therapy

Cardiovascular Disorders and Probable Dementia

Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia

[see Warnings and Precautions (5.1, 5.3), and Clinical Studies (14.3, 14.4)].

The WHI estrogen plus progestin substudy reported increased risks of DVT, pulmonary embolism (PE), stroke and myocardial infarction (MI) in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with daily oral CE (0.625 mg) combined with medroxyprogesterone acetate (MPA) [2.5 mg], relative to placebo

[see Warnings and Precautions (5.1), and Clinical Studies (14.3)].

The WHIMS estrogen plus progestin ancillary study of the WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 4 years of treatment with daily CE (0.625 mg) combined with MPA (2.5 mg), relative to placebo. It is unknown whether this finding applies to younger postmenopausal women

[see Warnings and Precautions (5.3), Use in Specific Populations (8.5), and Clinical Studies (14.4)].

Breast Cancer

The WHI estrogen plus progestin substudy also demonstrated an increased risk of invasive breast cancer

[see Warnings and Precautions (5.2), and Clinical Studies (14.3)].

In the absence of comparable data, these risks should be assumed to be similar for other doses of CE plus MPA, and other combinations and dosage forms of estrogens and progestins.

Estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.


What might happen if I take too much Vivelle-Dot?

Overdosage of estrogen may cause nausea, vomiting, breast tenderness, abdominal pain, drowsiness and fatigue, and withdrawal bleeding may occur in women. Treatment of overdose consists of discontinuation of Vivelle-Dot therapy with institution of appropriate symptomatic care.


How should I store and handle Vivelle-Dot?

How SuppliedVivelle-Dot (estradiol transdermal system), 0.025 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0365-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0365-45Vivelle-Dot (estradiol transdermal system), 0.0375 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0343-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0343-45Vivelle-Dot (estradiol transdermal system), 0.05 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0344-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0344-45Vivelle-Dot (estradiol transdermal system), 0.075 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0345-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0345-45Vivelle-Dot (estradiol transdermal system), 0.1 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0346-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0346-45 [*see DESCRIPTION (11)]How SuppliedVivelle-Dot (estradiol transdermal system), 0.025 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0365-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0365-45Vivelle-Dot (estradiol transdermal system), 0.0375 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0343-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0343-45Vivelle-Dot (estradiol transdermal system), 0.05 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0344-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0344-45Vivelle-Dot (estradiol transdermal system), 0.075 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0345-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0345-45Vivelle-Dot (estradiol transdermal system), 0.1 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0346-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0346-45 [*see DESCRIPTION (11)]How SuppliedVivelle-Dot (estradiol transdermal system), 0.025 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0365-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0365-45Vivelle-Dot (estradiol transdermal system), 0.0375 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0343-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0343-45Vivelle-Dot (estradiol transdermal system), 0.05 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0344-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0344-45Vivelle-Dot (estradiol transdermal system), 0.075 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0345-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0345-45Vivelle-Dot (estradiol transdermal system), 0.1 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0346-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0346-45 [*see DESCRIPTION (11)]How SuppliedVivelle-Dot (estradiol transdermal system), 0.025 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0365-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0365-45Vivelle-Dot (estradiol transdermal system), 0.0375 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0343-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0343-45Vivelle-Dot (estradiol transdermal system), 0.05 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0344-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0344-45Vivelle-Dot (estradiol transdermal system), 0.075 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0345-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0345-45Vivelle-Dot (estradiol transdermal system), 0.1 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0346-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0346-45 [*see DESCRIPTION (11)]How SuppliedVivelle-Dot (estradiol transdermal system), 0.025 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0365-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0365-45Vivelle-Dot (estradiol transdermal system), 0.0375 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0343-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0343-45Vivelle-Dot (estradiol transdermal system), 0.05 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0344-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0344-45Vivelle-Dot (estradiol transdermal system), 0.075 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0345-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0345-45Vivelle-Dot (estradiol transdermal system), 0.1 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0346-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0346-45 [*see DESCRIPTION (11)]How SuppliedVivelle-Dot (estradiol transdermal system), 0.025 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0365-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0365-45Vivelle-Dot (estradiol transdermal system), 0.0375 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0343-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0343-45Vivelle-Dot (estradiol transdermal system), 0.05 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0344-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0344-45Vivelle-Dot (estradiol transdermal system), 0.075 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0345-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0345-45Vivelle-Dot (estradiol transdermal system), 0.1 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0346-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0346-45 [*see DESCRIPTION (11)]How SuppliedVivelle-Dot (estradiol transdermal system), 0.025 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0365-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0365-45Vivelle-Dot (estradiol transdermal system), 0.0375 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0343-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0343-45Vivelle-Dot (estradiol transdermal system), 0.05 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0344-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0344-45Vivelle-Dot (estradiol transdermal system), 0.075 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0345-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0345-45Vivelle-Dot (estradiol transdermal system), 0.1 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0346-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0346-45 [*see DESCRIPTION (11)]How SuppliedVivelle-Dot (estradiol transdermal system), 0.025 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0365-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0365-45Vivelle-Dot (estradiol transdermal system), 0.0375 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0343-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0343-45Vivelle-Dot (estradiol transdermal system), 0.05 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0344-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0344-45Vivelle-Dot (estradiol transdermal system), 0.075 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0345-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0345-45Vivelle-Dot (estradiol transdermal system), 0.1 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0346-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0346-45 [*see DESCRIPTION (11)]How SuppliedVivelle-Dot (estradiol transdermal system), 0.025 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0365-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0365-45Vivelle-Dot (estradiol transdermal system), 0.0375 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0343-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0343-45Vivelle-Dot (estradiol transdermal system), 0.05 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0344-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0344-45Vivelle-Dot (estradiol transdermal system), 0.075 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0345-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0345-45Vivelle-Dot (estradiol transdermal system), 0.1 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0346-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0346-45 [*see DESCRIPTION (11)]How SuppliedVivelle-Dot (estradiol transdermal system), 0.025 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0365-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0365-45Vivelle-Dot (estradiol transdermal system), 0.0375 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0343-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0343-45Vivelle-Dot (estradiol transdermal system), 0.05 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0344-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0344-45Vivelle-Dot (estradiol transdermal system), 0.075 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0345-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0345-45Vivelle-Dot (estradiol transdermal system), 0.1 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0346-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0346-45 [*see DESCRIPTION (11)]How SuppliedVivelle-Dot (estradiol transdermal system), 0.025 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0365-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0365-45Vivelle-Dot (estradiol transdermal system), 0.0375 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0343-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0343-45Vivelle-Dot (estradiol transdermal system), 0.05 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0344-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0344-45Vivelle-Dot (estradiol transdermal system), 0.075 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0345-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0345-45Vivelle-Dot (estradiol transdermal system), 0.1 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0346-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0346-45 [*see DESCRIPTION (11)]How SuppliedVivelle-Dot (estradiol transdermal system), 0.025 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0365-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0365-45Vivelle-Dot (estradiol transdermal system), 0.0375 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0343-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0343-45Vivelle-Dot (estradiol transdermal system), 0.05 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0344-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0344-45Vivelle-Dot (estradiol transdermal system), 0.075 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0345-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0345-45Vivelle-Dot (estradiol transdermal system), 0.1 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0346-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0346-45 [*see DESCRIPTION (11)]How SuppliedVivelle-Dot (estradiol transdermal system), 0.025 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0365-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0365-45Vivelle-Dot (estradiol transdermal system), 0.0375 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0343-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0343-45Vivelle-Dot (estradiol transdermal system), 0.05 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0344-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0344-45Vivelle-Dot (estradiol transdermal system), 0.075 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0345-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0345-45Vivelle-Dot (estradiol transdermal system), 0.1 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0346-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0346-45 [*see DESCRIPTION (11)]How SuppliedVivelle-Dot (estradiol transdermal system), 0.025 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0365-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0365-45Vivelle-Dot (estradiol transdermal system), 0.0375 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0343-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0343-45Vivelle-Dot (estradiol transdermal system), 0.05 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0344-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0344-45Vivelle-Dot (estradiol transdermal system), 0.075 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0345-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0345-45Vivelle-Dot (estradiol transdermal system), 0.1 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0346-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0346-45 [*see DESCRIPTION (11)]How SuppliedVivelle-Dot (estradiol transdermal system), 0.025 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0365-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0365-45Vivelle-Dot (estradiol transdermal system), 0.0375 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0343-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0343-45Vivelle-Dot (estradiol transdermal system), 0.05 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0344-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0344-45Vivelle-Dot (estradiol transdermal system), 0.075 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0345-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0345-45Vivelle-Dot (estradiol transdermal system), 0.1 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0346-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0346-45 [*see DESCRIPTION (11)]How SuppliedVivelle-Dot (estradiol transdermal system), 0.025 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0365-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0365-45Vivelle-Dot (estradiol transdermal system), 0.0375 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0343-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0343-45Vivelle-Dot (estradiol transdermal system), 0.05 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0344-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0344-45Vivelle-Dot (estradiol transdermal system), 0.075 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0345-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0345-45Vivelle-Dot (estradiol transdermal system), 0.1 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0346-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0346-45 [*see DESCRIPTION (11)]How SuppliedVivelle-Dot (estradiol transdermal system), 0.025 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0365-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0365-45Vivelle-Dot (estradiol transdermal system), 0.0375 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0343-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0343-45Vivelle-Dot (estradiol transdermal system), 0.05 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0344-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0344-45Vivelle-Dot (estradiol transdermal system), 0.075 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0345-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0345-45Vivelle-Dot (estradiol transdermal system), 0.1 mg per dayPatient Calendar Pack of 8 Systems……………………………………….NDC 0078-0346-42Carton of 3 Patient Calendar Packs of 8 Systems…………………………NDC 0078-0346-45 [*see DESCRIPTION (11)]


&times

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

Endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol, at the receptor level.

The primary source of estrogen in normally cycling adult women is the ovarian follicle, which secretes 70 to 500 mcg of estradiol daily, depending on the phase of the menstrual cycle. After menopause, most endogenous estrogen is produced by conversion of androstenedione, secreted by the adrenal cortex, to estrone in the peripheral tissues. Thus, estrone and the sulfate conjugated form, estrone sulfate, are the most abundant circulating estrogens in postmenopausal women.

Estrogens act through binding to nuclear receptors in estrogen-responsive tissues. To date, 2 estrogen receptors have been identified. These vary in proportion from tissue to tissue.

Circulating estrogens modulate the pituitary secretion of the gonadotropins, luteinizing hormone (LH) and follicle stimulating hormone (FSH) through a negative feedback mechanism. Estrogens act to reduce the elevated levels of these hormones seen in postmenopausal women.

Non-Clinical Toxicology
Vivelle-Dot is contraindicated in women with any of the following conditions:

Estrogen-Alone Therapy

Endometrial Cancer

There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adding a progestin to estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding

[see Warnings and Precautions (5.2)].

Cardiovascular Disorders and Probable Dementia

Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or dementia

[see Warnings and Precautions (5.1, 5.3), and Clinical Studies (14.3, 14.4)].

The Women's Health Initiative (WHI) estrogen-alone substudy reported increased risks of stroke and deep vein thrombosis (DVT) in postmenopausal women (50 to 79 years of age) during 7.1 years of treatment with daily oral conjugated estrogens (CE) [0.625 mg]-alone, relative to placebo

[see Warnings and Precautions (5.1), and Clinical Studies (14.3)].

The WHI Memory Study (WHIMS) estrogen-alone ancillary study of the WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 5.2 years of treatment with daily CE (0.625 mg)-alone, relative to placebo. It is unknown whether this finding applies to younger postmenopausal women

[see Warnings and Precautions (5.3), Use in Specific Populations (8.5), and Clinical Studies (14.4)].

In the absence of comparable data, these risks should be assumed to be similar for other doses of CE and other dosage forms of estrogens.

Estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.

Estrogen Plus Progestin Therapy

Cardiovascular Disorders and Probable Dementia

Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia

[see Warnings and Precautions (5.1, 5.3), and Clinical Studies (14.3, 14.4)].

The WHI estrogen plus progestin substudy reported increased risks of DVT, pulmonary embolism (PE), stroke and myocardial infarction (MI) in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with daily oral CE (0.625 mg) combined with medroxyprogesterone acetate (MPA) [2.5 mg], relative to placebo

[see Warnings and Precautions (5.1), and Clinical Studies (14.3)].

The WHIMS estrogen plus progestin ancillary study of the WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 4 years of treatment with daily CE (0.625 mg) combined with MPA (2.5 mg), relative to placebo. It is unknown whether this finding applies to younger postmenopausal women

[see Warnings and Precautions (5.3), Use in Specific Populations (8.5), and Clinical Studies (14.4)].

Breast Cancer

The WHI estrogen plus progestin substudy also demonstrated an increased risk of invasive breast cancer

[see Warnings and Precautions (5.2), and Clinical Studies (14.3)].

In the absence of comparable data, these risks should be assumed to be similar for other doses of CE plus MPA, and other combinations and dosage forms of estrogens and progestins.

Estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.

An increased risk of stroke and DVT has been reported with estrogen-alone therapy. An increased risk of PE, DVT, stroke, and MI has been reported with estrogen plus progestin therapy. Should any of these occur or be suspected, estrogen with or without progestin therapy should be discontinued immediately.

Risk factors for arterial vascular disease (for example, hypertension, diabetes mellitus, tobacco use, hypercholesterolemia, and obesity) and/or venous thromboembolism (VTE) (for example, personal history or family history of VTE, obesity, and systemic lupus erythematosus) should be managed appropriately.

Stroke

In the WHI estrogen-alone substudy, a statistically significant increased risk of stroke was reported in women 50 to 79 years of age receiving daily CE (0.625 mg)-alone compared to women in the same age group receiving placebo (45 versus 33 per 10,000 women-years). The increase in risk was demonstrated in year 1 and persisted . Should a stroke occur or be suspected, estrogen-alone therapy should be discontinued immediately.

Subgroup analyses of women 50 to 59 years of age suggest no increased risk of stroke for those women receiving CE (0.625 mg)-alone versus those receiving placebo (18 versus 21 per 10,000 women-years).

In the WHI estrogen plus progestin substudy, a statistically significant increased risk of stroke was reported in women 50 to 79 years of age receiving CE (0.625 mg) plus MPA (2.5 mg) compared to women in the same age group receiving placebo (33 versus 25 per 10,000 women-years) . The increase in risk was demonstrated after the first year and persisted. Should a stroke occur or be suspected, estrogen plus progestin therapy should be discontinued immediately.

Coronary Heart Disease

In the WHI estrogen-alone substudy, no overall effect on coronary heart disease (CHD) events (defined as nonfatal MI, silent MI, or CHD death) was reported in women receiving estrogen-alone compared to placebo .

Subgroup analyses of women 50 to 59 years of age suggest a statistically nonsignificant reduction in CHD events reported in women receiving daily CE (0.625 mg) –alone compared to placebo in women less than 10 years since menopause (8 versus 16 per 10,000 women-years).

In the WHI estrogen plus progestin substudy, there was a statistically nonsignificant increased risk of CHD events reported in women receiving daily CE (0.625 mg) plus MPA (2.5 mg) compared to women receiving placebo (41 versus 34 per 10,000 women-years). An increase in relative risk was demonstrated in year 1, and a trend toward decreasing relative risk was reported in years 2 through 5 .

In postmenopausal women with documented heart disease (n=2,763, average 66.7 years of age), in a controlled clinical trial of secondary prevention of cardiovascular disease (Heart and Estrogen/Progestin Replacement Study; HERS), treatment with daily CE (0.625 mg) plus MPA (2.5 mg) demonstrated no cardiovascular benefit. During an average follow-up of 4.1 years, treatment with CE plus MPA did not reduce the overall rate of CHD events in postmenopausal women with established CHD. There were more CHD events in the CE plus MPA-treated group than in the placebo group in year 1, but not during the subsequent years. Two thousand three hundred twenty-one (2,321) women from the original HERS trial agreed to participate in an open-label extension of HERS, HERS II. Average follow-up in HERS II was an additional 2.7 years, for a total of 6.8 years overall. Rates of CHD events were comparable among women in the CE plus MPA group and the placebo group in the HERS, the HERS II, and overall.

Venous Thromboembolism

In the WHI estrogen-alone substudy, the risk of VTE (DVT and PE) was increased for women receiving daily CE (0.625 mg)-alone compared to placebo (30 versus 22 per 10,000 women-years), although only the increased risk of DVT reached statistical significance (23 versus 15 per 10,000 women-years). The increase in VTE risk was demonstrated during the first 2 years . Should a VTE occur or be suspected, estrogen-alone therapy should be discontinued immediately.

In the WHI estrogen plus progestin substudy, a statistically significant 2-fold greater rate of VTE was reported in women receiving daily CE (0.625 mg) plus MPA (2.5 mg) compared to women receiving placebo (35 versus 17 per 10,000 women-years). Statistically significant increases in risk for both DVT (26 versus 13 per 10,000 women-years) and PE (18 versus 8 per 10,000 women-years) were also demonstrated. The increase in VTE risk was demonstrated during the first year and persisted . Should a VTE occur or be suspected, estrogen plus progestin therapy should be discontinued immediately.

If feasible, estrogens should be discontinued at least 4 to 6 weeks before surgery of the type associated with an increased risk of thromboembolism, or during periods of prolonged immobilization.

The following serious adverse reactions are discussed elsewhere in labeling:

&times

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

&times

Review

Rate this treatment and share your opinion


Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

This medication has worked for me.




This medication has been easy for me to use.




Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
&times

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
&times

Tips

Tips

&times

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).